Perspective Therapeutics (NYSE:CATX) Rating Increased to Moderate Buy at Royal Bank of Canada

Perspective Therapeutics (NYSE:CATX) was upgraded by research analysts at Royal Bank of Canada from an “outperform” rating to a “moderate buy” rating in a report released on Tuesday, Marketbeat.com reports. The brokerage presently has a $16.00 price target on the stock, up from their previous price target of $15.00. Royal Bank of Canada’s price target would indicate a potential upside of 417.80% from the stock’s previous close.

Other research analysts have also issued reports about the company. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Perspective Therapeutics in a research report on Monday, March 31st. Brookline Capital Management upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Monday, March 10th. Wedbush restated an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, May 13th. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. Finally, Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Perspective Therapeutics presently has a consensus rating of “Buy” and an average target price of $12.63.

Perspective Therapeutics Trading Up 29.3%

Shares of Perspective Therapeutics stock opened at $3.09 on Tuesday. Perspective Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $16.55. The stock has a 50 day moving average of $2.27 and a 200 day moving average of $2.95.

Insider Transactions at Perspective Therapeutics

In related news, CFO Juan Graham purchased 33,333 shares of the stock in a transaction that occurred on Friday, March 28th. The shares were purchased at an average price of $2.25 per share, with a total value of $74,999.25. Following the completion of the acquisition, the chief financial officer now directly owns 35,354 shares in the company, valued at $79,546.50. This represents a 1,649.33% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Robert F. Williamson III purchased 38,145 shares of the stock in a transaction that occurred on Monday, March 31st. The shares were bought at an average cost of $2.14 per share, for a total transaction of $81,630.30. Following the acquisition, the director now owns 108,982 shares of the company’s stock, valued at approximately $233,221.48. The trade was a 53.85% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 115,696 shares of company stock worth $256,344. Corporate insiders own 3.72% of the company’s stock.

Hedge Funds Weigh In On Perspective Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Affinity Asset Advisors LLC boosted its holdings in Perspective Therapeutics by 71.1% in the 1st quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company’s stock valued at $4,738,000 after purchasing an additional 924,196 shares in the last quarter. MetLife Investment Management LLC boosted its holdings in Perspective Therapeutics by 40.9% in the 1st quarter. MetLife Investment Management LLC now owns 31,310 shares of the company’s stock valued at $67,000 after purchasing an additional 9,082 shares in the last quarter. HighTower Advisors LLC boosted its holdings in Perspective Therapeutics by 13.2% in the 1st quarter. HighTower Advisors LLC now owns 201,586 shares of the company’s stock valued at $429,000 after purchasing an additional 23,475 shares in the last quarter. Nuveen LLC purchased a new stake in Perspective Therapeutics in the 1st quarter valued at approximately $2,647,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Perspective Therapeutics by 6.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 434,085 shares of the company’s stock valued at $925,000 after purchasing an additional 27,119 shares in the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.